Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990092 | 1.00 | CTSS (0.44) | CTSSCTSKGAAALDH1A1L3MBTL1 | |
| SCHEMBL9972470 | 1.00 | CTSS (0.44) | CTSSCTSKGAAALDH1A1L3MBTL1 | |
| SCHEMBL7876246 | 0.87 | CTSS (0.43) | CTSSCTSKGAAALDH1A1L3MBTL1 | |
| SCHEMBL7878136 | 0.87 | CTSS (0.43) | CTSSCTSKGAAALDH1A1L3MBTL1 | |
| SCHEMBL28501721 | 0.85 | ALDH1A1 (0.56) | GAAALDH1A1L3MBTL1CYP2C9HTT | |
| SCHEMBL1983218 | 0.85 | MAPK1 (0.54) | CTSSCTSKALDH1A1MAPK1LMNA | |
| SCHEMBL1983219 | 0.85 | MAPK1 (0.54) | CTSSCTSKALDH1A1MAPK1LMNA | |
| SCHEMBL13778725 | 0.83 | CTSK (0.64) | CTSSCTSKALDH1A1CYP2C9HTT | |
| SCHEMBL15081482 | 0.83 | CTSK (0.64) | CTSSCTSKALDH1A1CYP2C9HTT | |
| SCHEMBL8203738 | 0.83 | CTSK (0.64) | CTSSCTSKALDH1A1CYP2C9HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8921514-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20120172290-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20150087618-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
| US-20120172290-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CTSS 445/4885CTSK 632/4885GAA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.